MedNoxa Inc.

An early stage wound care company commercializing an effective and affordable, oxygen generation and delivery bandage to promote the healing of acute and chronic wounds in an easier, cheaper and faster way.
Diabetes is the leading cause of non-traumatic amputation. Globally, a leg is lost to diabetes every 30 seconds. In the U.S. alone, the direct cost of treating diabetic foot ulcers is over $15B.

Even with all that spending, we average 200 amputations a day with a mortality rate higher than cancer. About 50% of patients with diabetic foot infections who have foot amputations die within five years. Treating diabetic wounds early and effectively can lead to healing and an ever-growing body of research supports the efficacy of topical oxygen. Topical oxygen research consistently indicates significantly higher rates of wound closure and faster time to closure compared to the standard of care. This research is summarized in an April 2017 CMS decision memo and the repeal of the national no-coverage determination on topical oxygen therapy.

MedNoxa’s solution is a patented, affordable, flexible wound dressing that generates concentrated oxygen gas from hydrogen peroxide for controllable, accurate delivery of oxygen to wounds to stimulate tissue growth and promote healing. We are commercializing a technology licensed from Purdue Research Foundation.
Our competitive advantage is the cost advantage achieved through the proprietary technology combined with a proprietary, low-cost, manufacturing process.

Company’s Keywords:

wound care, diabetic ulcer treatment, wound healing, oxygen based wound healing bandages